BNIP3 (BCL2 interacting protein 3) overexpression in myeloma cells, with special reference to its impact on mitochondria and apoptosis. Suggested as a tumor marker. It is thought to be a viable target for stopping residual hepatocellular carcinoma from growing quickly and spreading after radiation therapy but is insufficient to ablate the cancer. Breast cancer growth metastasis linked to obesity is significantly reduced by BNIP3, thereby slowing the cancer’s progression. Here, BNIP3 is linked to hepatocellular carcinoma.